Electroacupuncture can Modify Stress, Low-Grade Inflammation in the Duodenum, and Damage to the Intestinal Barrier in Rats with Functional Dyspepsia through the CRF Signaling Pathway
CONCLUSION: EA has been shown to improve the stress state of FD rats, inhibit the activation of mast cells in the duodenum, and reduce low-grade inflammatory response and damage to the intestinal mucosal barrier. It is believed that EA achieves these effects by modulating the expression of CRF and its receptors in the brain-gut interaction pathway through the CRF signaling pathway. This provides a new approach to treating FD.PMID:38591200 | DOI:10.2174/0113862073306526240403063736 (Source: Combinatorial Chemistry and High Throughput Screening)
Source: Combinatorial Chemistry and High Throughput Screening - April 9, 2024 Category: Chemistry Authors: Tong Liu Haili Wang Jiayi Liu Ruirui Tan Lili Chen Xurong Liang Ailin Li Chenxi Qi Zhaohui Wang Source Type: research
Electroacupuncture can Modify Stress, Low-Grade Inflammation in the Duodenum, and Damage to the Intestinal Barrier in Rats with Functional Dyspepsia through the CRF Signaling Pathway
CONCLUSION: EA has been shown to improve the stress state of FD rats, inhibit the activation of mast cells in the duodenum, and reduce low-grade inflammatory response and damage to the intestinal mucosal barrier. It is believed that EA achieves these effects by modulating the expression of CRF and its receptors in the brain-gut interaction pathway through the CRF signaling pathway. This provides a new approach to treating FD.PMID:38591200 | DOI:10.2174/0113862073306526240403063736 (Source: Combinatorial Chemistry and High Throughput Screening)
Source: Combinatorial Chemistry and High Throughput Screening - April 9, 2024 Category: Chemistry Authors: Tong Liu Haili Wang Jiayi Liu Ruirui Tan Lili Chen Xurong Liang Ailin Li Chenxi Qi Zhaohui Wang Source Type: research
Electroacupuncture can Modify Stress, Low-Grade Inflammation in the Duodenum, and Damage to the Intestinal Barrier in Rats with Functional Dyspepsia through the CRF Signaling Pathway
CONCLUSION: EA has been shown to improve the stress state of FD rats, inhibit the activation of mast cells in the duodenum, and reduce low-grade inflammatory response and damage to the intestinal mucosal barrier. It is believed that EA achieves these effects by modulating the expression of CRF and its receptors in the brain-gut interaction pathway through the CRF signaling pathway. This provides a new approach to treating FD.PMID:38591200 | DOI:10.2174/0113862073306526240403063736 (Source: Combinatorial Chemistry and High Throughput Screening)
Source: Combinatorial Chemistry and High Throughput Screening - April 9, 2024 Category: Chemistry Authors: Tong Liu Haili Wang Jiayi Liu Ruirui Tan Lili Chen Xurong Liang Ailin Li Chenxi Qi Zhaohui Wang Source Type: research
Proton Pump Inhibitors and Kidney Disease: Fact or Fiction?
Am J Nephrol. 2024 Apr 6. doi: 10.1159/000538755. Online ahead of print.ABSTRACTBACKGROUND: Proton pump inhibitors (PPI) are commonly prescribed medications for dyspepsia and gastroesophageal reflux. There are concerns about their use in the development of chronic kidney disease (CKD).SUMMARY: The available published literature fails to support an association with PPI and the development of CKD. Placebo-controlled trials demonstrate no difference on the incidence of CKD between placebo and PPI. If one examines the data according to the Bradford Hill perspective incorporating temporal relationship, strength of association, ...
Source: American Journal of Nephrology - April 7, 2024 Category: Urology & Nephrology Authors: Matthew Ryan Weir Source Type: research
Proton Pump Inhibitors and Kidney Disease: Fact or Fiction?
Am J Nephrol. 2024 Apr 6. doi: 10.1159/000538755. Online ahead of print.ABSTRACTBACKGROUND: Proton pump inhibitors (PPI) are commonly prescribed medications for dyspepsia and gastroesophageal reflux. There are concerns about their use in the development of chronic kidney disease (CKD).SUMMARY: The available published literature fails to support an association with PPI and the development of CKD. Placebo-controlled trials demonstrate no difference on the incidence of CKD between placebo and PPI. If one examines the data according to the Bradford Hill perspective incorporating temporal relationship, strength of association, ...
Source: American Journal of Nephrology - April 7, 2024 Category: Urology & Nephrology Authors: Matthew Ryan Weir Source Type: research
Proton Pump Inhibitors and Kidney Disease: Fact or Fiction?
Am J Nephrol. 2024 Apr 6. doi: 10.1159/000538755. Online ahead of print.ABSTRACTBACKGROUND: Proton pump inhibitors (PPI) are commonly prescribed medications for dyspepsia and gastroesophageal reflux. There are concerns about their use in the development of chronic kidney disease (CKD).SUMMARY: The available published literature fails to support an association with PPI and the development of CKD. Placebo-controlled trials demonstrate no difference on the incidence of CKD between placebo and PPI. If one examines the data according to the Bradford Hill perspective incorporating temporal relationship, strength of association, ...
Source: American Journal of Nephrology - April 7, 2024 Category: Urology & Nephrology Authors: Matthew Ryan Weir Source Type: research
Proton Pump Inhibitors and Kidney Disease: Fact or Fiction?
Am J Nephrol. 2024 Apr 6. doi: 10.1159/000538755. Online ahead of print.ABSTRACTBACKGROUND: Proton pump inhibitors (PPI) are commonly prescribed medications for dyspepsia and gastroesophageal reflux. There are concerns about their use in the development of chronic kidney disease (CKD).SUMMARY: The available published literature fails to support an association with PPI and the development of CKD. Placebo-controlled trials demonstrate no difference on the incidence of CKD between placebo and PPI. If one examines the data according to the Bradford Hill perspective incorporating temporal relationship, strength of association, ...
Source: American Journal of Nephrology - April 7, 2024 Category: Urology & Nephrology Authors: Matthew Ryan Weir Source Type: research
Proton Pump Inhibitors and Kidney Disease: Fact or Fiction?
Am J Nephrol. 2024 Apr 6. doi: 10.1159/000538755. Online ahead of print.ABSTRACTBACKGROUND: Proton pump inhibitors (PPI) are commonly prescribed medications for dyspepsia and gastroesophageal reflux. There are concerns about their use in the development of chronic kidney disease (CKD).SUMMARY: The available published literature fails to support an association with PPI and the development of CKD. Placebo-controlled trials demonstrate no difference on the incidence of CKD between placebo and PPI. If one examines the data according to the Bradford Hill perspective incorporating temporal relationship, strength of association, ...
Source: American Journal of Nephrology - April 7, 2024 Category: Urology & Nephrology Authors: Matthew Ryan Weir Source Type: research
Proton Pump Inhibitors and Kidney Disease: Fact or Fiction?
Am J Nephrol. 2024 Apr 6. doi: 10.1159/000538755. Online ahead of print.ABSTRACTBACKGROUND: Proton pump inhibitors (PPI) are commonly prescribed medications for dyspepsia and gastroesophageal reflux. There are concerns about their use in the development of chronic kidney disease (CKD).SUMMARY: The available published literature fails to support an association with PPI and the development of CKD. Placebo-controlled trials demonstrate no difference on the incidence of CKD between placebo and PPI. If one examines the data according to the Bradford Hill perspective incorporating temporal relationship, strength of association, ...
Source: American Journal of Nephrology - April 7, 2024 Category: Urology & Nephrology Authors: Matthew Ryan Weir Source Type: research
Proton Pump Inhibitors and Kidney Disease: Fact or Fiction?
Am J Nephrol. 2024 Apr 6. doi: 10.1159/000538755. Online ahead of print.ABSTRACTBACKGROUND: Proton pump inhibitors (PPI) are commonly prescribed medications for dyspepsia and gastroesophageal reflux. There are concerns about their use in the development of chronic kidney disease (CKD).SUMMARY: The available published literature fails to support an association with PPI and the development of CKD. Placebo-controlled trials demonstrate no difference on the incidence of CKD between placebo and PPI. If one examines the data according to the Bradford Hill perspective incorporating temporal relationship, strength of association, ...
Source: American Journal of Nephrology - April 7, 2024 Category: Urology & Nephrology Authors: Matthew Ryan Weir Source Type: research
Proton Pump Inhibitors and Kidney Disease: Fact or Fiction?
Am J Nephrol. 2024 Apr 6. doi: 10.1159/000538755. Online ahead of print.ABSTRACTBACKGROUND: Proton pump inhibitors (PPI) are commonly prescribed medications for dyspepsia and gastroesophageal reflux. There are concerns about their use in the development of chronic kidney disease (CKD).SUMMARY: The available published literature fails to support an association with PPI and the development of CKD. Placebo-controlled trials demonstrate no difference on the incidence of CKD between placebo and PPI. If one examines the data according to the Bradford Hill perspective incorporating temporal relationship, strength of association, ...
Source: American Journal of Nephrology - April 7, 2024 Category: Urology & Nephrology Authors: Matthew Ryan Weir Source Type: research
Proton Pump Inhibitors and Kidney Disease: Fact or Fiction?
Am J Nephrol. 2024 Apr 6. doi: 10.1159/000538755. Online ahead of print.ABSTRACTBACKGROUND: Proton pump inhibitors (PPI) are commonly prescribed medications for dyspepsia and gastroesophageal reflux. There are concerns about their use in the development of chronic kidney disease (CKD).SUMMARY: The available published literature fails to support an association with PPI and the development of CKD. Placebo-controlled trials demonstrate no difference on the incidence of CKD between placebo and PPI. If one examines the data according to the Bradford Hill perspective incorporating temporal relationship, strength of association, ...
Source: American Journal of Nephrology - April 7, 2024 Category: Urology & Nephrology Authors: Matthew Ryan Weir Source Type: research
Proton Pump Inhibitors and Kidney Disease: Fact or Fiction?
Am J Nephrol. 2024 Apr 6. doi: 10.1159/000538755. Online ahead of print.ABSTRACTBACKGROUND: Proton pump inhibitors (PPI) are commonly prescribed medications for dyspepsia and gastroesophageal reflux. There are concerns about their use in the development of chronic kidney disease (CKD).SUMMARY: The available published literature fails to support an association with PPI and the development of CKD. Placebo-controlled trials demonstrate no difference on the incidence of CKD between placebo and PPI. If one examines the data according to the Bradford Hill perspective incorporating temporal relationship, strength of association, ...
Source: American Journal of Nephrology - April 7, 2024 Category: Urology & Nephrology Authors: Matthew Ryan Weir Source Type: research
Proton Pump Inhibitors and Kidney Disease: Fact or Fiction?
Am J Nephrol. 2024 Apr 6. doi: 10.1159/000538755. Online ahead of print.ABSTRACTBACKGROUND: Proton pump inhibitors (PPI) are commonly prescribed medications for dyspepsia and gastroesophageal reflux. There are concerns about their use in the development of chronic kidney disease (CKD).SUMMARY: The available published literature fails to support an association with PPI and the development of CKD. Placebo-controlled trials demonstrate no difference on the incidence of CKD between placebo and PPI. If one examines the data according to the Bradford Hill perspective incorporating temporal relationship, strength of association, ...
Source: American Journal of Nephrology - April 7, 2024 Category: Urology & Nephrology Authors: Matthew Ryan Weir Source Type: research
Treatment of < em > Helicobacter pylori < /em > with potassium competitive acid blockers: A systematic review and meta-analysis
CONCLUSION: VPZ-based triple therapy outperformed conventional PPI-based triple therapy in eradicating H. pylori, positioning it as a highly effective first-line regimen. Additionally, TPZ-based triple therapy was non-inferior to classical PPI triple therapy.PMID:38577188 | PMC:PMC10989498 | DOI:10.3748/wjg.v30.i9.1213 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - April 5, 2024 Category: Gastroenterology Authors: Joseph Edwin Kanu Jonathan Soldera Source Type: research
